<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Afdhal, Nezam H.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Assessment of Liver Fibrosis With New Modalities</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-07 10:43:03</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">5-7</style></pages><abstract><style  face="normal" font="default" size="100%">Although liver biopsy is considered the gold standard method of assessment for liver fibrosis, it is being displaced by noninvasive testing, such as serum biomarkers, vibration-controlled transient elastography, magnetic resonance elastography, and acoustic radiation force impulse. However, it is important to understand how they perform, particularly in patients with stage 2 to 3 fibrosis.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>